Erratum: Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30mg/day versus aspirin 100mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) Study (Cerebrovascular Diseases (2009) 27 (509-518) DOI: 10.1159/000212671);Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: The prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study

Cerebrovascular Diseases

Volumn 27, Issue 5, 2009, Pages 509-518

  Bousser, M G ^a   Amarenco, P ^b   Chamorro, A ^c   Fisher, M ^d   Ford, I ^e   Fox, K ^f   Hennerici, M G ^h   Mattle, H P ⁱ   Rothwell, P M ^g  

^a HÔPITAL LARIBOISIÈRE   (France)

^b INSERM   (France)

^c HOSPITAL CLÍNIC   (Spain)

^d Memorial Health   (United States)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f ROYAL BROMPTON HOSPITAL   (United Kingdom)

^g JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ UNIVERSITY OF BERN   (Switzerland)

Author keywords

Antiplatelet therapy; Aspirin; Dementia; Ischemic stroke; PERFORM Study; Stroke prevention; Terutroban; TP receptor antagonist; Transient ischemic attack

Indexed keywords

ACETYLSALICYLIC ACID; TERUTROBAN;

ADULT; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SECONDARY PREVENTION; STROKE; TRANSIENT ISCHEMIC ATTACK;

EID: 64549164466     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000469131     Document Type: Erratum

References (37)

1. World Health Organization: The Atlas of Heart Disease and Stroke. WHO. http://www.who.int/cardiovascular-diseases/resources/atlas/en/index.html (accessed 2009).
2. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Steinberger J, Thorn T, Wilson M, Hong Y: Heart disease and stroke statistics 2008 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:e25-e146.
3. Capewell S, Morrison CE, McMurray JJ: Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart 1999;81:380-386.
4. Unal B, Critchley JA, Capewell S: Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 2004;109:1101-1107.
5. Hardoon SL, Whincup PH, Lennon LT, Wannamethee SG, Capewell S, Morris RW: How much of the recent decline in the incidence of myocardial infarction in British men can be explained by changes in cardiovascular risk factors? Evidence from a prospective population-based study. Circulation 2008;117:598-604.
6. Strong K, Mathers C, Bonita R: Preventing stroke: saving lives around the world. Lancet Neurol 2007;6:182-187.
7. Hackam DG, Spence JD: Combining multiple approaches for the secondary prevention of vascular events after stroke: a quantitative modeling study. Stroke 2007;38:1881-1885.
8. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T: Guidelines for prevention of stroke in patients with isch-emic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 2006;113:e409-e449.
9. Schneider JA, Arvanitakis Z, Bang W, Bennett DA: Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007;69: 2197-2204.
10. Hachinski V: Shifts in thinking about dementia. JAMA 2008;300:2172-2173.
11. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
12. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329-1339.
13. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study. 2. Dipyridamole and acetyl-salicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143:1-13.
14. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Ma-tias-Guiu J, Rupprecht HJ: Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-337.
15. Brown DL: Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment. Heart 2003;89:535-537.
16. Fiessinger JN: S18886, a new specific TP-re-ceptor antagonist, is safe and as effective as aspirin in inhibiting platelet aggregation in patients with peripheral arterial disease. Eur Heart J 2004;25:573.
17. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD: Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001;41:661-690.
18. Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA: The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vase Biol 2000; 20: 1724-1728.
19. Halushka MK, Halushka PV: Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A(2)? Circulation 2002;105:1620-1622.
20. Pratico D, Cheng Y, FitzGerald GA: TP or not TP: primary mediators in a close runoff? Arterioscler Thromb Vase Biol 2000; 20: 1695-1698.
21. Hong TT, Huang J, Driscoll E, Lucchesi BR: Preclinical evaluation of S18886 in an experimental model of coronary arterial thrombosis. J Cardiovasc Pharmacol 2006;48:239-248.
22. 2 receptor antagonist. J Thromb Haemost 2004;2:492-498.
23. 2 receptor activation mediates angiotensin II-induced postischemic neovasculariza-tion. Arterioscler Thromb Vase Biol 2006; 26:488-493.
24. Worth NF, Berry CL, Thomas AC, Campbell JH: S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. Atherosclerosis 2005;183:65-73.
25. Gaussem P, Reny JL, Thalamas C, Chatelain N, Kroumova M, Jude B, Boneu B, Fiessinger JN: The specific thromboxane receptor antagonist S18886: pharmacokinetic and phar-macodynamic studies. J Thromb Haemost 2005;3:1437-1445.
26. 2 receptor antagonist S18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 2003; 41:1198-1204.
27. Bal C, Crassard I, Simoneau G, Bergmann JF, Bousser MG, Drouet L: Effect of the TP receptor antagonist terutroban on experimental arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. Cerebrovasc Dis, submitted.
28. Xu S, Jiang B, Maitland KA, Bayat H, Gu J, Nadler JL, Corda S, Lavielle G, Verbeuren TJ, Zuccollo A, Cohen RA: The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice. Diabetes 2006;55:110-119.
29. Gelosa P, Nobili E, Gianella A, Blanc-Guillemaud V, Lerond L, Guerrini U, Tremoli E, Sironi L: S18886, a thromboxane A2 receptor antagonist, prevents occurrence of spontaneous brain damage in stroke-prone rats via anti-inflammatory activities. Cerebrovasc Dis 2007;23:137.
30. Shineman DW, Zhang B, Leight SN, Pratico D, Lee VM: Thromboxane receptor activation mediates isoprostane-induced increases in amyloid pathology in Tg2576 mice. J Neu-rosci 2008;28:4785-4794.
31. Kasner SE: Clinical interpretation and use of stroke scales. Lancet Neurol 2006;5:603-612.
32. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198.
33. Isaacs B, Kennie AT: The Set test as an aid to the detection of dementia in old people. Br J Psychiatry 1973; 123:467-470.
34. Zazzo R: Test des deux barrages. Actualités pédagogiques et psychologiques. Neuchâtel, Delachaux et Nestle, 1974, vol 7.
35. Lawton MP, Brody EM: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9:179-186.
36. Wade DT, Collin C: The Barthel ADL Index: a standard measure of physical disability? Int DisabilStud 1988;10:64-67.
37. Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox K, Hennerici MG, Mattle HP, Rothwell PM, on behalf of the PERFORM Study Investigators: The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population. Cerebrovasc Dis, in press.